Amersham International of the U.K. will acquire 14.9% of radioisotopesupplier Nordion International. Amersham is a participant in theinvestment group that won bidding last month to buy Nordion fromthe Canadian government. The $165 million (U.S. $144
Amersham International of the U.K. will acquire 14.9% of radioisotopesupplier Nordion International. Amersham is a participant in theinvestment group that won bidding last month to buy Nordion fromthe Canadian government. The $165 million (U.S. $144 million)acquisition remains subject to due diligence prior to a finalclosing.
Nordion was formerly a division of Atomic Energy of CanadaLtd. (AECL). The Canadian government divided AECL into two companiesin 1988 in preparation for its privatization. Nordion is the world'slargest supplier of technetium-99m for use in nuclear medicine,according to W. Paul O'Neill, Nordion president.
The pharmaceutical company also supplies the strontium basefor Squibb's CardioGen, a rubidium-82 imaging agent for positronemission tomography. Squibb and Nordion signed a three-year strontiumsupply agreement last year (SCAN 7/4/90).
The other company formed out of AECL is Theratronics International,a manufacturer of cobalt cancer therapy products, O'Neill said.Both firms are based in Kanata, Ontario.
Theratronics purchased Medical High Technology International,a Clearwater, FL, computed tomography developer, three years ago.MHTI, in turn, bought CT tube developer Meicor last year (SCAN8/29/90).
Canadian divestiture legislation limited foreign ownershipof Nordion to 25%. The lead partner in the winning investmentgroup is MDS Health Group of Etobicoke, Ontario. MDS is an employee-owned,diversified health-care company. It will purchase 80.1% of Nordion.
Among its many medical businesses, MDS operates in vitro diagnostictesting laboratories and nursing homes, provides home-health servicesand develops medical office buildings, according to informationsupplied by the Canadian Ministry of Finance.
The third investment partner, acquiring the remaining 5% ofNordion, is the Terry Fox Medical Research Foundation. This isa charity established to stimulate an industrial biotechnologybase in British Columbia.
Nordion maintains three processing facilities. Both the Kanatasite and Nordion Europe outside Brussels manufacture and marketreactor-produced isotopes, including technetium, and related equipment.A facility in Vancouver, B.C., manufacturers cyclotron-producedradioisotopes.
More than 90% of Nordion's $107 million (U.S. $93 million)in 1990 sales occurred outside of Canada. The firm created NordionEurope last year by acquiring assets of Belgium's Institut Nationaldes Radioelements.
BRIEFLY NOTED:
The Vanguard acquisition will allow Kodak to offer completeimaging systems for the cardiac cath market, said Joseph C. Barry,general manager for cardiology in the film vendor's Health Sciencesdivision.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.